• Subscribe
  • Magazine
  • Past Issues
  • Surveys
  • Industry Statistics
  • About Us
  • Members Only
  • Best Places to Work
    • Recent Quotes
    My Watchlist
    Indicators
    PennEnergy Stock Watch
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Mannkind Corp (NQ: MNKD )

    4.780 +0.030 (+0.63%)
    Streaming Delayed Price Updated: 4:00 PM EDT, Jun 18, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 1,922,537
    Open 4.760
    Bid (Size) 4.750 (4)
    Ask (Size) 4.800 (100)
    Prev. Close 4.750
    Today's Range 4.720 - 4.819
    52wk Range 3.170 - 5.750
    Shares Outstanding 264,305,532
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    Inhale-3 Study Results to be Presented During a 90-Minute Symposium on Saturday, June 22 at the American Diabetes Association’s 84th Scientific Sessions
    From MannKind
    Via GlobeNewswire
    MannKind to Establish Boston-Area Research & Development Foothold and Expand Portfolio of Dry Powder Inhalation Technology in Transaction With Pulmatrix
    From MannKind
    Via GlobeNewswire

    Performance

    YTD
    +21.94%
    +21.94%
    1 Month
    +1.70%
    +1.70%
    3 Month
    +2.36%
    +2.36%
    6 Month
    +22.25%
    +22.25%
    1 Year
    +18.91%
    +18.91%

    More News

    Read More
    MannKind (MNKD) Q1 2024 Earnings Call Transcript
    Via The Motley Fool
    Topics Earnings
    Exposures Financial
    Earnings Scheduled For February 27, 2024
    Via Benzinga
    MannKind Earnings Preview
    Via Benzinga
    MNKD Stock Earnings: MannKind Beats EPS, Beats Revenue for Q1 2024
    Via InvestorPlace
    MannKind Corporation Reports 2024 First Quarter Financial Results: Provides Clinical Development Update
    From MannKind
    Via GlobeNewswire
    MannKind Receives U.S. FDA Fast Track Designation for Clofazimine Inhalation Suspension for the Treatment of Nontuberculous Mycobacterial (NTM) Lung Disease
    From MannKind
    Via GlobeNewswire
    MannKind Corporation to Hold 2024 First Quarter Financial Results Conference Call on May 8, 2024
    From MannKind
    Via GlobeNewswire
    MannKind to Proceed With Phase 1 Nintedanib Dpi (Mnkd-201) Study for Pulmonary Fibrotic Diseases
    From MannKind
    Via GlobeNewswire
    MannKind Announces IND Clearance From U.S. FDA to Start Phase 3 Study of Clofazimine Inhalation Suspension for Nontuberculous Mycobacterial (NTM) Lung Disease
    From MannKind
    Via GlobeNewswire
    MannKind Repays Certain Debt Obligations
    From MannKind
    Via GlobeNewswire
    MannKind Announces CFO Transition
    From MannKind
    Via GlobeNewswire
    Why Mesoblast Shares Are Trading Higher By 13%? Here Are Other Stocks Moving In Monday's Mid-Day Session
    Via Benzinga
    Exposures Product Safety
    EQT, Genie Energy And Other Big Stocks Moving Lower On Monday
    Via Benzinga
    Topics Stocks
    Exposures US Equities
    What's Going On With MannKind Stock?
    Via Benzinga
    INHALE-3 Study’s Initial Meal Challenge Results Comparing Afrezza® Head-To-Head With Multiple Daily Injections (MDI) and Insulin Pumps
    From MannKind
    Via GlobeNewswire
    Cramer Says Sprout Social Is In A 'Hot Spot,' But This Energy Stock Is 'Too Down And Out'
    Via Benzinga
    MannKind Announces New Clinical Data From Inhale-3 Study to be Presented by Dr. Irl B. Hirsch at ATTD on March 8
    From MannKind
    Via GlobeNewswire
    MannKind Corporation Announces Participation at Upcoming Conferences
    From MannKind
    Via GlobeNewswire
    MannKind (MNKD) Q4 2023 Earnings Call Transcript
    Via The Motley Fool
    Topics Earnings
    Exposures Financial
    MannKind Corporation Reports 2023 Fourth Quarter and Full Year Financial Results: Provides Clinical Development Update
    From MannKind
    Via GlobeNewswire
    MannKind Corporation to Hold 2023 Fourth Quarter and Full Year Financial Results Conference Call on February 27, 2024
    From MannKind
    Via GlobeNewswire
    MannKind Announces Enrollment Goal Completion of INHALE-1 Pediatric Diabetes Trial Utilizing Afrezza®
    From MannKind
    Via GlobeNewswire
    3 Biotech Stocks to Sell in January Before They Crash and Burn
    Via InvestorPlace
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.